RecruitingNCT07467564
Dupilumab and mental health in people with moderate-to-severe eczema
About this title
Read the official source — NCT07467564Observational studyAges 12+Multiple countriesAnxiety
Understand this study
Who could participate?
Listed age limits: from 12 years.
- Listed locations
- Doha and 6 more locationsSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 24, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 184
- Sponsor
- Sanofi
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- Drug
- Locations
- Qatar, Saudi Arabia, United Arab Emirates
- Age range
- Over 12 Years
- Official registry ID
- NCT07467564
- Official title
Show the full official title
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis in Gulf Countries
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Doha, Qatar · Jeddah, Saudi Arabia · Abu Dhabi, United Arab Emirates
3 more locations
- Fujairah, United Arab Emirates
- Ras al-Khaimah, United Arab Emirates
- Sharjah city, United Arab Emirates
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Sanofi.
Does this study involve medication?
Yes. The study involves medication, including Dupilumab.
Who can participate?
Listed age limits: from 12 years.
Is this study still recruiting?
The registry lists this study as recruiting.
